Literature DB >> 4000641

Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.

R B Nussenblatt, A G Palestine, C C Chan, F Roberge.   

Abstract

Standardization of observations is recognized as fundamental to clinical research. The methodology for the evaluation of anterior segment inflammatory disease has become well accepted, while the ocular inflammatory standardization of the posterior segment has not been so well described or accepted. A system for the evaluation of vitreal inflammatory activity in patients with intermediate and posterior uveitis is presented. A series of photographs representing various degrees of fundus vitreal haze is depicted. The observer examines the eye with an indirect ophthalmoscope, then chooses the photograph which most closely simulates what is being seen. This technique is rapid and its reproducibility is helpful in standardizing clinical observations.

Entities:  

Mesh:

Year:  1985        PMID: 4000641     DOI: 10.1016/s0161-6420(85)34001-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  150 in total

1.  Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins.

Authors:  Benoît-Joseph Laventie; Hendrik Jan Rademaker; Maher Saleh; Ernie de Boer; Rick Janssens; Tristan Bourcier; Audrey Subilia; Luc Marcellin; Rien van Haperen; Joyce H G Lebbink; Tao Chen; Gilles Prévost; Frank Grosveld; Dubravka Drabek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year experience in an endemic area.

Authors:  Jolly Tsui; Mary Ho; Grace Lui; Timothy Li; Lijia Chen; Lawrence Iu; Marten Brelen; Alvin L Young
Journal:  Int Ophthalmol       Date:  2021-05-26       Impact factor: 2.031

3.  Phacoemulsification and Core Vitrectomy in Fuchs' Heterochromic Uveitis.

Authors:  Sadullah Keles; Osman Ondas; Orhan Ates; Metin Ekinci; Baki Kartal; Eren Arpali; Kenan Yildirim; Erdinc Ceylan; Orhan Baykal
Journal:  Eurasian J Med       Date:  2017-06

4.  Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.

Authors:  Kana Kuroyanagi; Tsutomu Sakai; Hideo Kohno; Kiichiro Okano; Goichi Akiyama; Ranko Aoyagi; Mayumi Inaba; Hiroshi Tsuneoka
Journal:  Jpn J Ophthalmol       Date:  2015-08-29       Impact factor: 2.447

5.  Mycophenolate mofetil monotherapy in the management of paediatric uveitis.

Authors:  P Y Chang; G P Giuliari; M Shaikh; P Thakuria; D Makhoul; C S Foster
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

6.  The visual field in toxoplasmic retinochoroiditis.

Authors:  M R Stanford; E A Tomlin; O Comyn; K Holland; C Pavesio
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

7.  The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study.

Authors:  P Tranos; R Scott; H Zambarakji; H Zambarajki; W Ayliffe; C Pavesio; D G Charteris
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

8.  Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Authors:  John H Kempen; Mark L Van Natta; Michael M Altaweel; James P Dunn; Douglas A Jabs; Susan L Lightman; Jennifer E Thorne; Janet T Holbrook
Journal:  Am J Ophthalmol       Date:  2015-09-18       Impact factor: 5.258

9.  Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation.

Authors:  Usama Shalaby
Journal:  Jpn J Ophthalmol       Date:  2016-12-10       Impact factor: 2.447

Review 10.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.